Randomized phase 2 study of bone‐targeted therapy containing strontium‐89 in advanced castrate‐sensitive prostate cancer

BACKGROUND Radiopharmaceutical use may improve the survival time of patients with castrate‐resistant prostate cancer and bone metastases. Whether androgen‐deprivation therapy (ADT) combined with bone‐targeted therapy provides a clinical benefit to patients with advanced castrate‐sensitive prostate c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2015-01, Vol.121 (1), p.69-76
Hauptverfasser:	Bilen, Mehmet Asim, Johnson, Marcella M., Mathew, Paul, Pagliaro, Lance C., Araujo, John C., Aparicio, Ana, Corn, Paul G., Tannir, Nizar M., Wong, Franklin C., Fisch, Michael J., Logothetis, Christopher J., Tu, Shi‐Ming
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use bone metastasis Bone Neoplasms - secondary Bone Neoplasms - therapy Combined Modality Therapy - methods Diphosphonates - administration & dosage Diphosphonates - therapeutic use Doxorubicin - administration & dosage Doxorubicin - therapeutic use Humans Imidazoles - administration & dosage Imidazoles - therapeutic use Male phase 2 prostate cancer Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy radiopharmaceutical Strontium Radioisotopes - administration & dosage Strontium Radioisotopes - therapeutic use strontium‐89 Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!